Home Blog

Peak Shares Upgraded in US from OTCQB(R) Venture Market to OTCQX(R) Best Market

0

Montreal, Quebec–(Newsfile Corp. – September 21, 2020) – Peak Positioning Technologies Inc. (CSE: PKK) (OTCQX: PKKFF) (“Peak” or the “Company”), an innovative Fintech service provider to the Chinese commercial lending sector, today announced that it has qualified to trade on the OTCQX® Best Market, upgrading from the OTCQB® Venture Market.

Peak’s common shares begin trading today on OTCQX under the symbol “PKKFF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.

The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market from the OTCQB Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors. Peak’s common shares will now trade alongside high-profile companies such as Air Canada, BNP Paribas and Deutsche Telekom, to name just a few.

“We are delighted to have reached this important step as part of our ongoing effort to connect with U.S. investors. We look forward to working with OTC Markets Group to help U.S. investors become more familiar with the Company,” commented Peak CEO, Johnson Joseph.

About OTC Markets Group Inc.:

OTC Markets Group Inc. operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 11,000 U.S. and global securities. Through OTC Link® ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.

About Peak Positioning Technologies Inc.:

Peak Positioning Technologies Inc. is the parent company of a group of innovative financial technology (Fintech) subsidiaries operating in China’s commercial lending industry. Peak’s subsidiaries use technology, analytics and artificial intelligence to create an ecosystem of lenders, borrowers and other participants in China’s commercial lending space where lending operations are conducted rapidly, safely, efficiently and with the utmost transparency. For more information: http://www.peakpositioning.com

For more information, please contact:

CHF Capital Markets
Cathy Hume, CEO
416-868-1079 ext.: 251
cathy@chfir.com

Peak Positioning Technologies Inc.
Johnson Joseph, President and CEO
514-340-7775 ext.: 501
investors@peakpositioning.com

Twitter: @PeakPositioning
Facebook: @peakpositioning
LinkedIn:
Peak Positioning
YouTube:
Peak Positioning

Forward-Looking Statements / Information:

This news release may include certain forward-looking information, including statements relating to business and operating strategies, plans and prospects for revenue growth, using words including “anticipate”, “believe”, “could”, “expect”, “intend”, “may”, “plan”, “potential”, “project”, “seek”, “should”, “will”, “would” and similar expressions, which are intended to identify a number of these forward-looking statements. Forward-looking information reflects current views with respect to current events and is not a guarantee of future performance and is subject to risks, uncertainties and assumptions. The Company undertakes no obligation to publicly update or review any forward-looking information contained in this news release, except as may be required by applicable laws, rules and regulations. Readers are urged to consider these factors carefully in evaluating any forward-looking information.

Soligenix’s RiVax(R) Program Back in Focus After Deadly Ricin Toxin Intercepted Before Reaching White House

0

New York, New York–(Newsfile Corp. – September 21, 2020) – Soligenix’s (NASDAQ: SNGX) RiVax® program is in focus after a failed attempt to send ricin-laced letters to the White House last week raised fresh concerns about the deadly toxin. Those letters, including others addressed to Texas law enforcement agencies, were intercepted before delivery on Thursday. That news helped focus attention toward Soligenix’s RiVax® program, which is considered the leading ricin-poisoning vaccine program in the world to protect against exposure to this deadly substance.

The interest in Soligenix’s (NASDAQ: SNGX) program started trending after it was announced that the lethal ricin toxin was again used to potentially harm government leaders. Letters to the White House were addressed to President Trump and were intercepted at the final off-site processing facility before being sent to the White House mailroom. All US mail that is addressed to the White House and other federal agencies in the Washington area are irradiated before final delivery and get processed through a sorting facility that samples the air for suspicious substances.

Despite the slim chances of ricin-laced packages reaching the White House, the event nonetheless highlights the importance of developing a vaccine against this deadly substance. Soligenix is leading that race.

RiVax® Program Timely And Necessary

The potentially deadly events again demonstrate the importance of developing a vaccine against a ricin toxin that is lethal and yet easily manufactured. Ricin, a white powder, can induce irreversible symptoms within four hours of exposure and may cause death within 48-72 hours.

Its mechanism of action causes cell death once it penetrates the cell membrane, and it typically penetrates cells within 4 hours of exposure. Depending on the route of exposure (ingestion, inhalation, or injection), ricin toxin produces different initial symptoms. Regardless of the exposure method, though, ricin poisoning will result in death with sufficient exposure 100% of the time. Currently, there are no FDA-approved prophylactic or post-exposure therapies for ricin toxin exposure.

At Soligenix, RiVax® is one of two biodefense programs being developed through its Public Health Solutions business segment. The other, ThermoVax®, is a critical component of making a vaccine candidate’s temperature stable. Combining the two programs, positions RiVax® as the most advanced development-stage ricin treatment vaccine platform in the world. It may also be the most promising means to protect against exposure to ricin during chemical warfare. That warfare can include domestic events like what occurred last week.

In Phase I studies, Soligenix demonstrated that RiVax®, containing an abbreviated version of ricin toxin A chain with no biological activity, induces a non-toxic immunogenic response, while also demonstrating safety and tolerability in healthy volunteers. Importantly, the antibodies induced through immunization with RiVax® demonstrated complete protection from a lethal dose of aerosolized ricin in a rhesus macaques vaccine trial. The company is expected to seek expedited FDA approval for the vaccine under the “Animal Rule” that relies on studies successfully conducted in non-human primates. The benefits are compelling.

RiVax® Therapeutic Benefits Presented

The vaccine’s therapeutic benefits were presented at the Fourth International Conference on Vaccines Research and Development Development in 2018. Posters showed that RiVax® induces the adaptive immune system to produce antibodies that recognize and bind ricin toxin, preventing it from getting inside cells and killing them. Intramuscular injection of RiVax® stimulates the production of IgG and other antibodies, which are produced and circulated within the body to eradicate ricin, whether inhaled, eaten, or injected.

Further, the RiVax® vaccine candidate uses one of the safest vaccination approaches known – using a modified inactivated protein component of the ricin toxin itself to raise antibody responses, combined with an alum adjuvant to boost the body’s response to the vaccine. Also, RiVax® uses Soligenix’s proprietary ThermoVax® technology to create a vaccine which is stable for long-term storage (e.g., at least 12 months) even at very high temperatures (e.g., 40°C or 104°F). This means the RiVax® protein may be stored for long periods allowing it to be stockpiled for future use.

That stockpiling advantage is critical because potential therapies for ricin intoxication are generally limited for use within four hours of poisoning. Thus, because poisoning events are often of unknown origin and its point of delivery virtually limitless, a four-hour time limit for treatment is hugely problematic. In response, a strategically placed stockpile of RiVax® could be utilized for national defense and distributed quickly using a combination of logistical resources. Notably, to meet and finance a potential global opportunity for its vaccine candidate, Soligenix is earning tremendous financial support from outside agencies.

To date, RiVax® has been funded by non-dilutive grants awarded from the NIH (approximately $25 million thus far) and through a $21.2 million contract entered into with the NIH in 2014. Soligenix is also evaluating the opportunity to apply for a priority review voucher (PRV), which can be a valuable asset to the RiVax® program. These PRV’s are transferable, and recent PRV’s have sold for approximately $100 million in the biotech and pharma sector.

ThermoVax® Adds Critical Value RiVax®

A critical component that can potentially inspire an expedited review of RiVax® is ThermoVax®. One aspect of this proprietary stabilizing platform technology allows vaccines comprised of an aluminum salt adjutant to be kept out of cold storage without affecting its potency. The technique can be a breakthrough to eliminate the need for cold storage, and its applications can provide game-changing treatment in the battlefield, during extreme power-outage situations, and during large scale triage situations. It may also be instrumental in preventing large-scale domestic incidents.

ThermoVax® technology has already shown demonstrably positive results with RiVax®. Independent studies showed that ThermoVax® can provide potency protection for the RiVax® vaccine for at least one year at 104° Fahrenheit. Additionally, ThermoVax® demonstrated its ability to protect vaccine candidates’ potency to treat anthrax, HPV, and Ebola for at least twelve weeks at the same high temperatures.

Combining the two programs creates a compelling argument that the RiVax® program should be immediately brought to the desk of bio-defense decision-makers, who should evaluate the immediate and long-term threat from this easy to develop toxin. They should then take action to protect their citizens.

Most importantly, the benefits of ThermoVax® should not be underappreciated. It may offer the best solution to allow for easy storage and provide a unique ability to allow for a national and strategic stockpile of essential vaccines. It may be, by far, a best-in-class solution for multiple vaccine candidates.

Near-Term Catalysts For Soligenix

Currently trading at a sharp discount to analyst pricing models, Soligenix is well-positioned to further its growth by capitalizing on several clinical initiatives. Although RiVax® will get new attention this week, the company has at least four other programs targeting markets that can each generate hundreds of millions in potential peak revenues.

Thus, even with risk discounts applied to its clinical programs and at least two potential catalysts expected by year’s end, that value may start to build ahead of the results.

Now, with RiVax® in focus, those forward-looking revenue models may be worthy of a new appraisal, enticing a revision to financial projections that placed potential revenue from RiVax® past 2023.

At the very least, RiVax® may offer another near-term catalyst for Soligenix and create a substantial revenue-generating opportunity from worldwide governments that are having to address national defense and security as a priority. The events last week may put an exclamation point on that initiative.

Disclaimer

This communication was produced by PCG Digital Holdings, LLC, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this may be ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). PCG may be compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy.

PCG is not a registered or licensed broker, dealer, broker-dealer, investment adviser nor investment manager, nor does PCG engage in any activities that would require such registrations. PCG does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services to or statements about its clients should never be construed as any endorsement of or opinion about any security of any client. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other similar product or service regardless of whether such security, product, or service is referenced in this communication. Further, nothing in this communication is intended to provide tax, legal, or investment advice and nothing in this communication should be construed as a recommendation to buy, sell or hold any investment or security or to engage in any investment strategy or transaction. For full disclaimers, including compensation received for professional services, please visit www.pcgadvisory.com/disclosures.

Contact:

PCG Digital
info@pcgadvisory.com

GreenStar Biosciences Announces First Closing of Private Placement

0
Reading Time: 3 minutes

Vancouver, British Columbia–(Newsfile Corp. – September 21, 2020) – GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) (“GreenStar” or the “Company“), is pleased to announce that it has completed a first closing of its previously announced non-brokered private placement of units (the “Units“) of up to Cdn$4,000,000 (the “Offering“) for gross proceeds of $831,748.16 (the “First Tranche Closing“). The First Tranche Closing consisted of the issuance of an aggregate of 10,396,852 Units at a price of $0.08 per Unit. Each Unit consists of one common share in the capital of the Company (each a “Share“) and one-half of one common share purchase warrant (each whole warrant, a “Warrant“). Each Warrant entitles the subscriber to acquire one additional Share at a price of $0.20 per Warrant until March 31, 2022.

On the closing of the final tranche of the Offering, the Company will pay to Peak Asset Management (“Peak“) aggregate finder’ fees equal to 8% of the funds raised from investors procured or introduced by Peak and finders warrants (“Finders Warrants“) equal to 8% of the Units sold to investors introduced or procured by Peak in connection with the Offering. Each Finders Warrant is exercisable into one Share at an exercise price of $0.20 until March 31, 2022.

Proceeds from the Offering are expected to be used to initiate clinical studies with N-Acetylcysteine (“NAC“) and psilocybin, general working capital, product development and marketing. Although the Company intends to use the proceeds of the Offering as described above, the actual allocation of proceeds may vary from the uses set out above depending on future operations, events or opportunities.

All Shares and Warrants comprising the Units and the Finders Warrants issued pursuant to the Offering are subject to a statutory four month and one day hold period from the date of issue in accordance with applicable Canadian securities laws. None of the Units will be registered under the United States Securities Act of 1933, as amended, and none may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About GreenStar

GreenStar is a growth-oriented technology and services company that provides real estate, financial, management, IP and branding support to businesses. The Company operates a growing portfolio of tenant partner companies focused on transformational medicine and applies refined strategies to help partner companies reach their full potential. Based in Vancouver, BC, GreenStar intends to facilitate growth through acquisitions and development of additional assets, products and technologies by leveraging its capital markets, branding and operational expertise.

For further information please contact:

GreenStar Biosciences Corp.
Thomas Baird, CEO
info@greenstarbiosciences.com
Tel: (604) 834-9499

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. Certain statements included in this release, including statements regarding the Company’s proposed use of proceeds of the Offering, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulations. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including that the Company may determine to use the proceeds in a manner different than that currently expected; changes to the regulatory environment; and that the current Board and management may not be able to attain the Company’s corporate goals and objectives. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Powered by WPeMatico

GreenStar Biosciences Announces First Closing of Private Placement

0
Reading Time: 3 minutes

Vancouver, British Columbia–(Newsfile Corp. – September 21, 2020) – GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) (“GreenStar” or the “Company“), is pleased to announce that it has completed a first closing of its previously announced non-brokered private placement of units (the “Units“) of up to Cdn$4,000,000 (the “Offering“) for gross proceeds of $831,748.16 (the “First Tranche Closing“). The First Tranche Closing consisted of the issuance of an aggregate of 10,396,852 Units at a price of $0.08 per Unit. Each Unit consists of one common share in the capital of the Company (each a “Share“) and one-half of one common share purchase warrant (each whole warrant, a “Warrant“). Each Warrant entitles the subscriber to acquire one additional Share at a price of $0.20 per Warrant until March 31, 2022.

On the closing of the final tranche of the Offering, the Company will pay to Peak Asset Management (“Peak“) aggregate finder’ fees equal to 8% of the funds raised from investors procured or introduced by Peak and finders warrants (“Finders Warrants“) equal to 8% of the Units sold to investors introduced or procured by Peak in connection with the Offering. Each Finders Warrant is exercisable into one Share at an exercise price of $0.20 until March 31, 2022.

Proceeds from the Offering are expected to be used to initiate clinical studies with N-Acetylcysteine (“NAC“) and psilocybin, general working capital, product development and marketing. Although the Company intends to use the proceeds of the Offering as described above, the actual allocation of proceeds may vary from the uses set out above depending on future operations, events or opportunities.

All Shares and Warrants comprising the Units and the Finders Warrants issued pursuant to the Offering are subject to a statutory four month and one day hold period from the date of issue in accordance with applicable Canadian securities laws. None of the Units will be registered under the United States Securities Act of 1933, as amended, and none may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About GreenStar

GreenStar is a growth-oriented technology and services company that provides real estate, financial, management, IP and branding support to businesses. The Company operates a growing portfolio of tenant partner companies focused on transformational medicine and applies refined strategies to help partner companies reach their full potential. Based in Vancouver, BC, GreenStar intends to facilitate growth through acquisitions and development of additional assets, products and technologies by leveraging its capital markets, branding and operational expertise.

For further information please contact:

GreenStar Biosciences Corp.
Thomas Baird, CEO
info@greenstarbiosciences.com
Tel: (604) 834-9499

Disclaimer for Forward Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. Certain statements included in this release, including statements regarding the Company’s proposed use of proceeds of the Offering, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are risks detailed from time to time in the filings made by the Company with securities regulations. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including that the Company may determine to use the proceeds in a manner different than that currently expected; changes to the regulatory environment; and that the current Board and management may not be able to attain the Company’s corporate goals and objectives. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Powered by WPeMatico

Datametrex Receives Third COVID-19 Order from TV Production Company

0

Toronto, Ontario–(Newsfile Corp. – September 21, 2020) –  Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that it has received a third Purchase Order (“P.O.”) for COVID-19 screening solutions from Are You Afraid of the Dark Inc., a Canadian horror anthology television miniseries based in Vancouver, British Columbia.

The miniseries is produced by Nickelodeon Productions and distributed by MTV Networks in the United States and YTV in Canada, a Corus Entertainment company. Nickelodeon, now in its 41st year, is the number one entertainment brand for kids. Nickelodeon and all related titles, characters and logos are trademarks of Viacom Inc.

The initial P.O. is for approximately $210,000 for a month, commencing on October 5, 2020. This production is scheduled to run for three (3) months, totalling $630,000. Datametrex anticipates that it will have little or no upfront costs associated with importing and selling these test kits.

As previously stated, Vancouver is the third-largest production centre in North America, worth CDN $3.2 Billion during 2018/19, according to Creative BC. British Columbia is home to several world-class Film and TV studios, including Bridge Studios, Mammoth Studios, Vancouver Film Studios, North Shore Studios, Ironwood Studios, Canadian Motion Picture Park, and The Crossing Studios.

Entire film and TV production in Canada represent $8.92 Billion in production volume, and full-time equivalent jobs represent 179,000 workers. In March 2020, the industry stopped worldwide, including in Vancouver, which represents 37% of Canadian Productions. The surrounding areas of Vancouver had 46 productions filming, which does not include the TV commercial market. Each of the shows potentially had a minimum of 100 people in their film crew.1

The next largest film and television market is Ontario, which represents 34% of Canadian productions. In 2019, Toronto’s film and television industry directly employed more than 28,000 people representing $3.17 Billion in production volume.

Additionally, with Canada having far fewer cases of COVID-19 than in the United States on a per capita basis according to data compiled by Johns Hopkins University, it demonstrates that Canada is a safer jurisdiction for filming and an advocate for the film industry, with our testing kits, collection services and labs already set up.

“With Vancouver productions quickly returning to the studios and filming, we feel that this is the tip of the iceberg for new film business for COVID-19 screening business,” said Marshall Gunter, CEO of the Company.

About Datametrex

Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email: mgunter@datametrex.com

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.


1 Source: CreativeBC Film Commission

Navigator Acquisition Corp. to Acquire Brazilian Green Energy Producers Pacto Energia

0

Vancouver, British Columbia–(Newsfile Corp. – September 18, 2020) – Navigator Acquisition Corp. (TSXV: NAQ.P) (“Navigator“) is pleased to announce that it has entered into a letter of intent dated September 16, 2020, with Pacto Energia S.A. (“Pacto“) pursuant to which Navigator proposes to acquire a number of subsidiaries of Pacto in exchange for the issuance of securities of Navigator (the “Pacto Transaction“). The Pacto Transaction will result in a reverse take-over of Navigator where the existing shareholders of Pacto will own approximately 82.9% of the outstanding common shares of Navigator upon completion of the transaction. Navigator, after completion of the Pacto Transaction, is referred to in this news release as the “Resulting Issuer”. Upon completion of the Pacto Transaction, it is anticipated that the Resulting Issuer will be a Tier 2 Energy Issuer.

Trading in the common shares of Navigator (the “Navigator Common Shares“) has been halted in accordance with the policies of the TSX Venture Exchange (the “TSXV“) and will remain halted until such time as all required documentation in connection with the Pacto Transaction has been filed with and accepted by the TSXV and permission to resume trading has been obtained from the TSXV.

The Qualifying Transaction

Navigator is a capital pool company and intends that the Pacto Transaction will constitute its “Qualifying Transaction” under the Capital Pool Companies policy (the “CPC Policy“) of the TSXV. The Pacto Transaction is arm’s length and is therefore not a Non-Arm’s Length Qualifying Transaction under the CPC Policy. Accordingly, the CPC Policy does not require Navigator to obtain shareholder approval of the Pacto Transaction.

As consideration for the acquisition of a number of subsidiaries of Pacto, holders of issued and outstanding ordinary shares of Pacto (“Pacto Common Shares“) will exchange their Pacto subsidiaries for Navigator Common Shares, in accordance with an exchange ratio (the “Exchange Ratio“) to be determined by Navigator and Pacto following receipt of financial advice.

The subsidiaries that will go into the Pacto deal detailed:

(a) 75% of the stock capital of Capim Branco Energia Solar SPE Ltda; Located in the Minas Gerais state of Brazil our 5.88MWp solar plant which has just issued its first invoice, therefore our 15-year contract with Algar Telecom, one of the largest telecom companies in the state of Minas Gerais will be able to be enjoyed fully by NAV, having the 1st payment made in October 2020. As explained before, because of the pandemic we had a delay in the connection of this plant to the grid.

(b) 15% of Atlas Energia Solar SPE Ltda: UFV Atlas I UFV Atlas II; Located in the Minas Gerais state of Brazil our Atlas 2.5 MWp solar plant, had in February 2020 its 1st phase of 500 KWp connected to the grid generating a net result of BRL 23.1 thousand in the 1H 2020. We expect to connect the 2nd phase with the remaining 2 MWp until next February which should generate a net result of BRL 230 thousand in the year of 2021.

(c) 100% of Evolution Comercializadora de Energia Elétrica e Gás Natural Ltda; Located in the São Paulo state of Brazil, our energy trading company, due to the low volume of business caused by the pandemic. We are still closing the financials for Evolution and 1H 2020 should come with a positive result of approximately BRL 200 thousand.

The current issued and outstanding share capital of Navigator consists of 16,930,000 Navigator Common Shares. Navigator has granted its directors and officers options to purchase an additional 1,693,000 Navigator Common Shares at an exercise price of $0.10 per share, and 500,000 compensation options to the agent under its initial public offering at an exercise price of $0.10 per share. The fully-diluted share capital of Navigator is 19,123,000 Navigator Common Shares.

Currently there are 1000 Pacto Common Shares issued and outstanding on a non-diluted and fully diluted basis. Pacto is controlled by its CEO Rodrigo Pedroso who owns 70% of the Pacto Common Shares and Eduardo Alves Pacto’s Senior Partner and Director of Business Development who owns 30% of the Pacto Common Shares.

Additional Resulting Issuer Shares will be issued to certain key Pacto management on achieving certain performance milestones. The nature of the performance milestones, and the number of Resulting Issuer Shares to be issued, will be described in the definitive agreement and announced in a subsequent news release.

Certain number of the Resulting Issuer Shares issued to the principals of Pacto who will become management of the Resulting Issuer, will be subject to escrow in accordance with TSXV policies. The final structure of the Pacto Transaction is subject to the receipt of tax, corporate and securities law advice for both Navigator and Pacto.

The Pacto transaction is expected to proceed on a cashless basis, hence no cash will be raised at the Qualifying Transaction. However, the company does plan to raise capital after presenting its audited financial statements for 2020.

No deposit or advance has been made or is anticipated to be made by Navigator to Pacto in connection with the Pacto Transaction.

About Pacto

Pacto Energia S.A. is a privately held Brazilian conglomerate of companies that offers solutions in energy for more than 18 years and has in its portfolio more than 7 GW of plants and projects of generation by renewable energy.

The company was incorporated under the laws of Brazil in 2001 by an experienced in-country management team. Pacto is headquartered in Sao Paulo, with over 7 GW of projects in green energy diversely spread within Brazil.

Pacto financials for 2019 and H1 of 2020 can be found below in the Appendix 1 of this press release.

Following are the information on the significant vendors of Pacto with their respected incorporation locations:

MERITO COMERCIALIZACAO DE ENERGIA ELETRICA LTDA. – state of São Paulo – Brazil
BOVEN COMERCIALIZADORA DE ENERGIA LTDA., state of São Paulo – Brazil
ELECTRA COMERCIALIZADORA DE ENERGIA LTDA, state of Paraná – Brazil
ECEL – ELETRON COMERCIALIZADORA DE ENERGIA LTDA, state of Pernambuco – Brazil
TRADENER LIMITADA, state of Paraná – Brazil
EPOP COOP – Cooperativa de micro e mini geração de energia elétrica, state of Goiás – Brazil
ALGAR TELECOM, state of Minas Gerais – Brazil

Pacto is not a reporting issuer and its securities are not listed or posted for trading on any stock exchange. Further information about Pacto, including financial information, will be provided in a subsequent news release.

Insiders of the Resulting Issuer

Upon completion of the Pacto Transaction, the board of directors (the “Board“) and management of the Resulting Issuer will be reconstituted so that five members of the Board will be nominated by Pacto and two members of the Board will be nominated by Navigator. It is anticipated that Rodrigo Pedroso will be an insider of the Resulting Issuer by virtue of his position as a director of the Resulting Issuer.

Rodrigo Ferreira Fonseca Pedroso – Owner of 70% (58% after the QT) of Pacto Energia.

Founder and CEO

Civil Engineer from PUC/GO – Pontifícia Universidade Católica de Goiás, specialist in Project Management from FGV – Fundação Getúlio Vargas, in Hydroelectric Generation from PAPUC – Pennsylvania Public Utility Commission, in Wind Generation from DEWI Institute, in Energy Trading from Universidade Presbiteriana Mackenzie and is currently a student at Harvard University, taking class 57 of the OPM (Owners and President Management Program).

Has over 18 years of experience in the electricity sector in the areas of generation, transmission, distribution and trading. Before founding the Company, worked at ANEEL – National Electric Energy Agency. Currently, besides being CEO of Pacto Energia Group, is also a member of the board of directors of ABSOLAR – Brazilian Solar Photovoltaic Energy Association, and Energy Director of FIESP – Federation of Industries of the State of São Paulo.

Eduardo Constantino Alves – Owner of 30% (24.9% after the QT) of Pacto Energia.

Senior Partner and Director of Business Development

Bachelor’s degree in Business Administration from the IESB University of Brasília, specialist in foreign trade, from Insper São Paulo. He has more than 10 years of experience in the area of Mobility, Urban / Road Transport and Real Estate Development. Before becoming a partner at Pacto Energia, he worked at União Incorporadora.

Additional information about the remaining proposed directors and officers of the Resulting Issuer will be provided in an update once the parties enter into a definitive agreement.

Significant Conditions to Closing

The completion of the Pacto Transaction is subject to a number of conditions precedent, including but not limited to satisfactory due diligence reviews, negotiation and execution of definitive transaction documentation, approval by the boards of directors of each of Navigator and Pacto, approval of Pacto shareholders, and obtaining necessary third-party approvals. There can be no assurance that the Pacto Transaction will be completed as proposed or at all.

Sponsorship

Sponsorship of a Qualifying Transaction may be required by the TSXV unless a waiver from the sponsorship requirement is available. Navigator intends to apply for a waiver from sponsorship for the Pacto Transaction on the basis, among other things, that the Resulting Issuer will operate in a highly-regulated industry. There is no assurance that a waiver from this requirement will be obtained.

About Navigator Acquisition Corp.

Navigator is a capital pool company created pursuant to the policies of the TSXV. It does not own any assets, other than cash or cash equivalents and its rights under the Letter of Intent. The principal business of Navigator is to identify and evaluate opportunities for the acquisition of an interest in assets or businesses and, once identified and evaluated, to negotiate an acquisition or participation subject to acceptance by the TSXV so as to complete a qualifying transaction in accordance with the policies of the TSXV.

Completion of the Pacto Transaction is subject to a number of conditions, including but not limited to, TSXV acceptance and if applicable pursuant to TSXV requirements, majority of the minority shareholder approval. Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the filing statement to be prepared in connection with the Pacto Transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. Navigator assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking- statements unless and until required by securities laws applicable to Navigator. Additional information identifying risks and uncertainties is contained in filings by Navigator with the Canadian securities regulators, which filings are available at

Figure 2

To view an enhanced version of Figure 2, please visit:
https://orders.newsfilecorp.com/files/6247/64153_ef3a660a14d70a73_002full.jpg

NOT FOR DISTRIBUTION TO UNITED STATES WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. THIS NEWS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY OF THE SECURITIES IN THE UNITED STATES. THE SECURITIES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “U.S. SECURITIES ACT”) OR ANY STATE SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO

U.S. PERSONS UNLESS REGISTERED UNDER THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS OR AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE. THIS NEWS RELEASE DOES NOT CONSTITUTE AN OFFER OR SALE OF SECURITIES IN THE UNITED STATES.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64153

CSE Bulletin: Delist – Rubicon Organics Inc. (ROMJ and ROMJ.WT)

0

Toronto, Ontario–(Newsfile Corp. – le 18 septembre/September 2020)

At the request of the company the common shares and share purchase warrants of Rubicon Organics Inc. will be delisted at market close on September 21, 2020.

The Company has announced the shares will continue to trade on TSX Venture Exchange.

For further information please see the issuer’s press release.

_________________________________

À la demande de la société, les actions ordinaires et les bons de souscription d’actions de Rubicon Organics Inc. seront radiés à la clôture du marché le 21 septembre 2020.

La société a annoncé que les actions continueront de se négocier à la Bourse de croissance TSX.

Pour plus d’informations, veuillez consulter le communiqué de presse de l’émetteur.

Date :

Market Close/Clôture du marchés le 21 septembre/September 2020

Symbol(s)/Symbole(s) :

ROMJ and ROMJ.WT

 

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com

Pour toute question, pour obtenir de l’information supplémentaire veuillez communiquer avec le service des inscriptions au 416 367-7340 ou par courriel à l’adresse: Listings@thecse.com

Lendified Announces Changes to the Board of Directors and the Filing of Its Subsidiary’s Audited Financial Statements

0

Toronto, Ontario–(Newsfile Corp. – September 18, 2020) – Lendified Holdings Inc. (TSXV: LHI) (formerly, Hampton Bay Capital Inc.) (the “Company” or “Lendified“) is pleased to announce the appointment of Guy Charette as an independent non-executive Director of the Company, effective immediately. Mr. Charette is a corporate finance lawyer with over thirty years’ experience in the areas of securities, corporate finance as well as mergers and acquisitions in Toronto and Montreal. Although primarily involved in the resource sector, he has also been involved in other areas such as medical technologies, industrial companies as well as having acted for many underwriters on various types of securities offerings. His corporate finance activities have included projects in many parts of the world including Africa, Europe and South America. Mr. Charette has a particular expertise in developing innovative financial structures designed to match the needs of both issuers and investors.

In addition, Lendified announces that Kevin Clark has resigned from the Board of Directors of the Company. The Board of Directors thanks Mr. Clark for his service to Lendified and for his assistance in aiding the turnaround efforts of the Company and wishes him well in his future endeavours.

The Company is also pleased to announce, further to its press releases of June 25, 2020 and July 3, 2020, that it has filed the audited annual financial statements of Lendified Privco Holding Corporation (“Privco“), a wholly-owned subsidiary of the Company acquired through the Company’s qualifying transaction announced on December 24, 2019 (the “Qualifying Transaction“), for the period ended December 31, 2019 (the “Privco Annual Statements“). The Privco Annual Statements as well as Privco’s interim financial report for the period ended March 31, 2020 (the “Privco Interim Report“) were required to be filed in connection with the Qualifying Transaction. The Corporation expects to file the Privco Interim Report shortly. On August 5, 2020 the Corporation filed the interim financial report of the Corporation for the period ended March 31, 2020, together with its related management discussion & analysis (“MD&A“).

The Ontario Securities Commission (“OSC“) issued a failure-to-file cease trade order on July 9, 2020 (the “FFCTO“) in respect of all of the securities of the Corporation for failing to file certain continuous disclosure documents in a timely manner. The FFCTO remains in effect until revoked by the OSC.

ABOUT LENDIFIED HOLDINGS INC.

Lendified, a company located in Ontario, Canada, is a Canadian FinTech company operating both a lending platform which provides working capital loans to small businesses across Canada through a wholly-owned subsidiary, as well as a software as a service technology platform providing AI-enabled credit origination and analytics to financial institutions across Canada through another wholly-owned subsidiary, JUDI.AI. The Company announced its intention to sell JUDI.AI in its press release of July 7, 2020.

Further Information

For further information regarding Lendified, please contact:

Troy Wright, Chief Executive Officer and Director
(647) 381-9218
troy.wright@lendified.com

Neither the TSXVE nor its Regulation Services Provider (as that term is defined in the policies of the TSXVE) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release may contain forward-looking statements which reflect the Company’s current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “plan, “estimate”, “expect”, “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industries in which the Company participates; others are more specific to the Company. The Company’s ongoing quarterly filings should be consulted for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. Management assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

Eric Sprott files Early Warning Report for Freegold Ventures Limited

0

Toronto, Ontario–(Newsfile Corp. – September 18, 2020) –  On September 18, 2020, Eric Sprott, through 2176423 Ontario Ltd., a corporation which is beneficially owned by him, acquired a total of 40,032,226 common shares of Freegold Ventures Limited ( Company) and 20,016,113 common share purchase warrants pursuant to the conversion of subscription receipts originally acquired on May 26, June 2 and July 29, 2020. After conversion, Mr. Sprott now beneficially owns and controls 78,948,504 common shares and 37,162,502, common share purchase warrants representing approximately 24.2% of the outstanding common shares on a non-diluted basis and 31.9% on a partially diluted basis assuming exercise of all such warrants. This represents an increase of approximately 8.3% on a non-diluted basis and 10.5% on a partially diluted basis from what was reported in the previously filed Early Warning Report of July 30, 2020 (without assuming conversion of the subscription receipts). Prior to the conversion, Mr. Sprott beneficially owned and controlled 38,916,278 common shares, 17,146,502 common share purchase warrants and 40,032,226 Subscription receipts each convertible into one common share and one-half of one common share purchase warrant (representing approximately 14.6% of the then outstanding common shares on a non-diluted basis and 31.9% on a partially diluted basis assuming exercise of all such warrants and conversion of such subscription receipts).

The shares were acquired by Mr. Sprott, through 2176423 Ontario Ltd. for investment purposes. Mr. Sprott has a long-term view of the investment and may acquire additional securities of the Company including on the open market or through private acquisitions or sell securities of the Company including on the open market or through private dispositions in the future depending on market conditions, reformulation of plans and/or other relevant factors. The Company is located at 888 – 700 West Georgia Street, Vancouver, British Columbia, V6Y 1G5. A copy of 2176423 Ontario Ltd.’s early warning report will appear on the Company’s profile on SEDAR and may also be obtained by calling Mr. Sprott’s office at 416-945-3294 (200 Bay Street, Suite 2600, Royal Bank Plaza, South Tower, Toronto, Ontario M5J 2J1)

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64124

Peak Announces Rebranding Plans and Provides Preview of Upcoming Website

0

Montreal, Quebec–(Newsfile Corp. – September 18, 2020) – Peak Positioning Technologies Inc. (CSE: PKK) (OTCQB: PKKFF) (“Peak” or the “Company”), an innovative Fintech service provider to the Chinese commercial lending sector, today announced its plans to change its name to “Peak Fintech Group” and to rebrand the Company to better reflect the collective business operations of its subsidiaries.

Peak will hold a virtual special meeting of its shareholders on November 9, 2020 to put the proposed name change to a vote. The Company’s shareholders on record as of October 5, 2020 will receive more details in the mail in the coming days regarding the special meeting of shareholders.

A temporary landing page with a preview of the Company’s upcoming new website is currently available at www.peakfintechgroup.com. The full website will replace the temporary landing page following the special meeting of shareholders.

Link to Peak CEO Presentation on Wall Street Reporter “Next Super Stock” Conference

Peak would also like to invite those who were unable to watch its CEO’s presentation on Wall Street Reporter’s “Next Super Stock” livestream conference on Wednesday September 16, 2020 to view a recording of the event by clicking on the following link: https://youtu.be/91G6-lo-eO0

About Peak Positioning Technologies Inc.:

Peak Positioning Technologies Inc. is the parent company of a group of innovative financial technology (Fintech) subsidiaries operating in China’s commercial lending industry. Peak’s subsidiaries use technology, analytics and artificial intelligence to create an ecosystem of lenders, borrowers and other participants in China’s commercial lending space where lending operations are conducted rapidly, safely, efficiently and with the utmost transparency. For more information: http://www.peakpositioning.com

For more information, please contact:

CHF Capital Markets
Cathy Hume, CEO
416-868-1079 ext.: 251
cathy@chfir.com

Peak Positioning Technologies Inc.

Johnson Joseph, President and CEO
514-340-7775 ext.: 501
investors@peakpositioning.com

Twitter: @PeakPositioning
Facebook: @peakpositioning
LinkedIn: Peak Positioning
YouTube: Peak Positioning

Forward-Looking Statements / Information:

This news release may include certain forward-looking information, including statements relating to business and operating strategies, plans and prospects for revenue growth, using words including “anticipate”, “believe”, “could”, “expect”, “intend”, “may”, “plan”, “potential”, “project”, “seek”, “should”, “will”, “would” and similar expressions, which are intended to identify a number of these forward-looking statements. Forward-looking information reflects current views with respect to current events and is not a guarantee of future performance and is subject to risks, uncertainties and assumptions. The Company undertakes no obligation to publicly update or review any forward-looking information contained in this news release, except as may be required by applicable laws, rules and regulations. Readers are urged to consider these factors carefully in evaluating any forward-looking information.

- Advertisement -

Get in touch

2,685FollowersFollow
2,363FollowersFollow

Recent Posts

Most Popular

Peak Shares Upgraded in US from OTCQB(R) Venture Market to OTCQX(R) Best Market

Montreal, Quebec--(Newsfile Corp. - September 21, 2020) - Peak Positioning Technologies Inc. (CSE: PKK) (OTCQX: PKKFF) ("Peak" or the "Company"), an innovative Fintech service...

Soligenix’s RiVax(R) Program Back in Focus After Deadly Ricin Toxin Intercepted Before Reaching White...

New York, New York--(Newsfile Corp. - September 21, 2020) - Soligenix's (NASDAQ: SNGX) RiVax® program is in focus after a failed attempt to send...

GreenStar Biosciences Announces First Closing of Private Placement

Reading Time: 3 minutes Vancouver, British Columbia–(Newsfile Corp. – September 21, 2020) – GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) (“GreenStar” or...

GreenStar Biosciences Announces First Closing of Private Placement

Reading Time: 3 minutes Vancouver, British Columbia–(Newsfile Corp. – September 21, 2020) – GreenStar Biosciences Corp. (CSE: GSTR) (OTC Pink: GTSIF) (“GreenStar” or...

Datametrex Receives Third COVID-19 Order from TV Production Company

Toronto, Ontario--(Newsfile Corp. - September 21, 2020) -  Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the "Company" or "Datametrex") is pleased...